Trulicity

Country: Unjoni Ewropea

Lingwa: Ingliż

Sors: EMA (European Medicines Agency)

Ixtrih issa

Ingredjent attiv:

dulaglutide

Disponibbli minn:

Eli Lilly Nederland B.V.

Kodiċi ATC:

A10BJ05

INN (Isem Internazzjonali):

dulaglutide

Grupp terapewtiku:

Drugs used in diabetes, Blood glucose lowering drugs, excl. insulins

Żona terapewtika:

Diabetes Mellitus, Type 2

Indikazzjonijiet terapewtiċi:

Trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Sommarju tal-prodott:

Revision: 17

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

2014-11-21

Fuljett ta 'informazzjoni

                                72
B. PACKAGE LEAFLET
73
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
TRULICITY 0.75 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 1.5 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 3 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 4.5 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
dulaglutide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Trulicity is and what it is used for
2.
What you need to know before you use Trulicity
3.
How to use Trulicity
4.
Possible side effects
5.
How to store Trulicity
6.
Contents of the pack and other information
1.
WHAT TRULICITY IS AND WHAT IT IS USED FOR
Trulicity contains an active substance called dulaglutide and is used
to lower blood sugar (glucose) in
adults and children aged 10 years and above, with type 2 diabetes
mellitus and can help prevent heart
disease.
Type 2 diabetes is a condition in which your body does not make enough
insulin, and the insulin that
your body produces does not work as well as it should.
When this happens, sugar (glucose) builds up in the blood.
Trulicity is used:
-
on its own if your blood sugar is not properly controlled by diet and
exercise alone, and you
can’t take metformin (another diabetes medicine).
-
or with other medicines for diabetes when they are not enough to
control your blood sugar
levels. These other medicines may be medicines taken by mouth and/or
insulin given by
injection.
It is important to continue to follow the advice on diet and exercise
given to you by your doctor,
pharmac
                                
                                Aqra d-dokument sħiħ
                                
                            

Karatteristiċi tal-prodott

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Trulicity 0.75 mg solution for injection in pre-filled pen
Trulicity 1.5 mg solution for injection in pre-filled pen
Trulicity 3 mg solution for injection in pre-filled pen
Trulicity 4.5 mg solution for injection in pre-filled pen
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Trulicity 0.75 mg solution for injection in pre-filled pen
Each pre-filled pen contains 0.75 mg of dulaglutide* in 0.5 ml
solution.
Trulicity 1.5 mg solution for injection in pre-filled pen
Each pre-filled pen contains 1.5 mg of dulaglutide* in 0.5 ml
solution.
Trulicity 3 mg solution for injection in pre-filled pen
Each pre-filled pen contains 3 mg of dulaglutide* in 0.5 ml solution.
Trulicity 4.5 mg solution for injection in pre-filled pen
Each pre-filled pen contains 4.5 mg of dulaglutide* in 0.5 ml
solution.
*produced in CHO cells by recombinant DNA technology.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear, colourless solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Type 2 Diabetes Mellitus
Trulicity is indicated for the treatment of patients 10 years and
above with insufficiently controlled
type 2 diabetes mellitus as an adjunct to diet and exercise
•
as monotherapy when metformin is considered inappropriate due to
intolerance or
contraindications
•
in addition to other medicinal products for the treatment of diabetes.
For study results with respect to combinations, effects on glycaemic
control and cardiovascular events,
and the populations studied, see sections 4.4, 4.5 and 5.1.
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_ _
Posology
_Adults _
_ _
_Monotherapy _
The recommended dose is 0.75 mg once weekly.
_Add-on therapy_
The recommended dose is 1.5 mg once weekly.
If needed,
•
the 1.5 mg dose can be increased after at least 4 weeks to 3 mg once
weekly.
•
the 3 mg dose can be increased after at least 4 weeks to 4.5 mg once
weekly.
The maximum dose is 4.5 mg once weekly.
_Paediatri
                                
                                Aqra d-dokument sħiħ
                                
                            

Dokumenti f'lingwi oħra

Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Bulgaru 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Bulgaru 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Spanjol 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Spanjol 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ċek 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ċek 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Daniż 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Daniż 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ġermaniż 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ġermaniż 16-03-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ġermaniż 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Estonjan 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Estonjan 16-03-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Estonjan 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Grieg 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Grieg 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Franċiż 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Franċiż 16-03-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Franċiż 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Taljan 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Taljan 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Latvjan 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Latvjan 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Litwanjan 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Litwanjan 16-03-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Litwanjan 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ungeriż 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ungeriż 16-03-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ungeriż 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Malti 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Malti 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Olandiż 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Olandiż 16-03-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Olandiż 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Pollakk 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Pollakk 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Portugiż 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Portugiż 16-03-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Portugiż 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Rumen 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Rumen 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Slovakk 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Slovakk 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Sloven 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Sloven 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Finlandiż 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Finlandiż 16-03-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Finlandiż 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Svediż 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Svediż 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Norveġiż 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Norveġiż 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Iżlandiż 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Iżlandiż 16-03-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Kroat 16-03-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Kroat 16-03-2023

Fittex twissijiet relatati ma 'dan il-prodott

Ara l-istorja tad-dokumenti